Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer.

Fiche publication

Date publication

décembre 2018

Journal

Oncotarget

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine , Dr BOREL Christian , Dr GUIHARD Sébastien , Dr JUNG Alain , Pr PETIT Thierry , Dr THIERY Alicia , Dr DEMARCHI Martin , Dr COLIAT Pierre , Dr BURGY Mickaël

Tous les auteurs :
Borel C, Regnier-Gavier O, Carinato H, Guihard S, Antoni D, Demarchi M, Sirlin F, Exinger D, Petit-Jean E, Thiery A, Bronner G, Schultz P, Flesch H, Frasie V, Prébay D, Petit T, Jung AC, Burgy M, Coliat P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30680071

Résumé

The EXTREME protocol is the standard of care for recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC) in first line. Beyond the first-line except immunotherapy, poor efficacy was reported by second-line chemotherapy. Re-challenge strategies based on a repetition of the first line with platinum and cetuximab regimens might have been an option to consider.